Sugi Predict

Sugi Predict / Targets / XPA

XPA

DNA repair protein complementing XP-A cells · P23025 · XPA on Sugi Atlas →

697 patent compounds predicted against XPA, 518 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL29524569 SCHEMBL29524569 0.85 18/20
SCHEMBL19654559 SCHEMBL19654559 0.85 18/20
SCHEMBL29388794 SCHEMBL29388794 0.85 18/20
SCHEMBL19654076 SCHEMBL19654076 0.85 18/20
SCHEMBL29385593 SCHEMBL29385593 0.85 18/20
SCHEMBL29388116 SCHEMBL29388116 0.85 18/20
SCHEMBL30679196 SCHEMBL30679196 0.85 17/20
SCHEMBL30679197 SCHEMBL30679197 0.85 17/20
SCHEMBL29385900 SCHEMBL29385900 0.85 17/20
SCHEMBL29388482 SCHEMBL29388482 0.84 17/20
SCHEMBL19644258 SCHEMBL19644258 0.76 17/20
SCHEMBL19644259 SCHEMBL19644259 0.76 17/20
SCHEMBL20847992 SCHEMBL20847992 0.76 17/20
SCHEMBL29524675 SCHEMBL29524675 0.75 17/20
SCHEMBL29385646 SCHEMBL29385646 0.72 17/20
SCHEMBL19644199 SCHEMBL19644199 1.00 16/20
SCHEMBL19644200 SCHEMBL19644200 1.00 16/20
SCHEMBL19644318 SCHEMBL19644318 1.00 16/20
SCHEMBL19644341 SCHEMBL19644341 1.00 16/20
SCHEMBL19644342 SCHEMBL19644342 1.00 16/20

Clinical trials — most relevant to XPA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer PHASE2UNKNOWN
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma PHASE1/PHASE2RECRUITING
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery PHASE1/PHASE2ACTIVE_NOT_RECRUITING
NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer PHASE1/PHASE2RECRUITING
Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC) PHASE2COMPLETED
S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction PHASE2COMPLETED
Selinexor, Cyclophosphamide and Prednisone in Myeloma PHASE2COMPLETED
Satraplatin and Prednisone to Treat Prostate Cancer PHASE2COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment PHASE2ACTIVE_NOT_RECRUITING
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer PHASE1COMPLETED
A Trial of Selinexor, Ruxolitinib and Methylprednisolone PHASE1RECRUITING
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers PHASE1RECRUITING
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC nanUNKNOWN
Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum nanCOMPLETED
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome nanUNKNOWN
Treatment of Chronic Lymphocytic Leukemia nanUNKNOWN
XPAND Trial: Enhancing XP Photoprotection Activities - New Directions nanCOMPLETED
Spironolactone and XPB-1 Integrity in the TFIIH Complex nanENROLLING_BY_INVITATION
Natural History Study for DNA Repair Disorders nanRECRUITING
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） nanRECRUITING
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 nanCOMPLETED
Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy. nanUNKNOWN
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate nanCOMPLETED
Aerobic Exercise and Telomere Length in Patients With Heart Failure. nanUNKNOWN
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. nanUNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews nanCOMPLETED
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients nanACTIVE_NOT_RECRUITING
A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates nanCOMPLETED
Telomere Repair Gene Mutation in Inflammatory Bowel Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a XPA binder may also engage these)

ProteinNameSimilarity
Q64267 — 0.999 Q64267 →
P27088 — 0.998 P27088 →
P27089 — 0.987 P27089 →
MNAT1 CDK-activating kinase assembly factor MAT1 0.979 landscape →
O08837 — 0.975 O08837 →
Q8N806 — 0.975 Q8N806 →
Q2KJC1 — 0.975 Q2KJC1 →
P92948 — 0.975 P92948 →
E1C760 — 0.975 E1C760 →
Q8K339 — 0.974 Q8K339 →
Q6PFL6 — 0.974 Q6PFL6 →
Q69ZX6 — 0.973 Q69ZX6 →
Q5RAD5 — 0.973 Q5RAD5 →
Q6A068 — 0.973 Q6A068 →
Q5ZJ85 — 0.973 Q5ZJ85 →
Q91WR3 — 0.973 Q91WR3 →
Q2KIA6 — 0.973 Q2KIA6 →
Q3UJB0 — 0.973 Q3UJB0 →
Q6U6G5 — 0.973 Q6U6G5 →
A2AQ19 — 0.973 A2AQ19 →
Q1RMM1 — 0.972 Q1RMM1 →
CDC5L Cell division cycle 5-like protein 0.972 landscape →
Q9Z315 — 0.972 Q9Z315 →
Q2IBC3 — 0.972 Q2IBC3 →
Q6PII3 — 0.972 Q6PII3 →
Q922U1 — 0.972 Q922U1 →
Q8N1G2 — 0.972 Q8N1G2 →
PRPF3 U4/U6 small nuclear ribonucleoprotein Prp3 0.972 landscape →
Q9CWV6 — 0.971 Q9CWV6 →
Q99PL6 — 0.971 Q99PL6 →